Inquiry Basket
Loading ......
Octreotide, a synthetic octapeptide somatostatin analog, is a cornerstone pharmacotherapy in the management of neuroendocrine tumors (NETs). By mimicking the inhibitory actions of endogenous somatostatin, octreotide suppresses the secretion of bioactive peptides and amines responsible for the debilitating symptoms of functional NETs, including carcinoid syndrome, VIPomas, and glucagonomas. Beyond symptomatic relief, octreotide exerts antiproliferative effects that delay tumor progression, making it a first-line systemic therapy for well-differentiated, somatostatin-receptor-positive gastroenteropancreatic NETs. The long-acting formulations of octreotide have revolutionized chronic NET management, but the wide interpatient variability in pharmacokinetics underscores the growing need for robust therapeutic drug monitoring (TDM) tools. Competitive enzyme-linked immunosorbent assays (ELISAs) have emerged as the method of choice for routine octreotide quantification, offering an ideal balance of sensitivity, specificity, throughput, and cost-effectiveness for both clinical and research settings.
Figure 1.Octreotide Mechanism in Neuroendocrine Tumors.
Neuroendocrine tumors are a heterogeneous group of neoplasms arising from neuroendocrine cells throughout the body, most commonly in the gastroenteropancreatic tract and lungs. Characterized by often-indolent growth yet potential for hormone hypersecretion and malignant progression, NETs present distinct therapeutic challenges. Octreotide exerts its effects by binding to somatostatin receptors (SSTRs), particularly SSTR2 and SSTR5, which are overexpressed on the surface of well-differentiated NET cells. This binding triggers a cascade of downstream effects: inhibition of hormone secretion from neuroendocrine cells, reduction of splanchnic blood flow, and direct antiproliferative signaling that stabilizes tumor growth.
The major clinical indications for octreotide include:
Despite the well-established efficacy of octreotide, interpatient variability in drug exposure is substantial. Factors contributing to pharmacokinetic variability include differences in body weight, renal function, hepatic metabolism, injection-site absorption, and concomitant medications. Furthermore, the development of anti-drug antibodies (ADAs) in a subset of patients can accelerate octreotide clearance and reduce drug bioavailability, leading to subtherapeutic exposure and diminished clinical response. Conversely, impaired renal function — a common comorbidity in elderly NET patients — may result in octreotide accumulation and dose-dependent adverse effects including gastrointestinal disturbances, biliary sludge formation, and glucose homeostasis dysregulation. Therapeutic drug monitoring addresses these challenges by enabling individualized dose optimization. Measurement of trough octreotide concentrations (Cmin) immediately before the next scheduled dose provides a reliable indicator of steady-state drug exposure. In patients experiencing symptom breakthrough despite standard dosing, a low trough level suggests subtherapeutic exposure amenable to dose escalation, while a therapeutic trough level points toward biological resistance necessitating alternative therapies such as peptide receptor radionuclide therapy (PRRT) or everolimus. Routine TDM also facilitates the early detection of ADA-mediated clearance, guiding timely intervention before clinical deterioration occurs. As precision oncology continues to reshape NET care, quantitative octreotide monitoring is becoming an essential component of evidence-based treatment algorithms.
Accurate bioanalytical measurement of octreotide concentrations constitutes an indispensable pillar of modern NET patient care and biopharmaceutical development. The Octreotide ELISA Kit delivers a regulatory-compliant immunoassay solution to resolve key analytical challenges including interpatient pharmacokinetic variability, tachyphylaxis assessment, and dose-response optimization. This kit is engineered with optimized antibody-antigen binding pairs, validated across human clinical serum and plasma matrices, and designed to generate reproducible, quantitative data acceptable for clinical trial submissions and translational research reporting.
Figure 2. Octreotide Competitive ELISA Kit Workflow & Applications.
| Kits | Details |
| Octreotide ELISA Kit | Clinical TDM for NET patients receiving octreotide therapy; dose optimization and interval adjustment; identification of patients with subtherapeutic trough levels; ZES therapy monitoring; clinical trial PK/PD analysis; biosimilar comparability studies; pharmacovigilance and long-term safety monitoring |
| Human Octreotide ELISA Kit | Competitive immunoassay for in vitro quantitative measurement of octreotide in human serum or plasma; exhibits high specificity with no cross-reactivity with endogenous somatostatin or other somatostatin analogues; validated for serum and plasma matrices; designed for therapeutic drug monitoring, dose optimization, and pharmacokinetic studies in NET and ZES patients |
Octreotide competitive ELISA kits serve a broad spectrum of applications spanning clinical care, pharmaceutical development, and translational research:
| Clinical and Research Applications | Details |
| Clinical Therapeutic Drug Monitoring | In routine clinical practice, trough-level octreotide monitoring informs individualized dose titration for NET patients on long-acting SSA therapy. Patients with carcinoid syndrome who experience breakthrough flushing or diarrhea despite standard dosing benefit from TDM-guided management: low trough concentrations warrant dose escalation or interval reduction, while therapeutic trough levels suggest the need for second-line therapies. For patients on high-dose octreotide regimens (above-label dosing), TDM identifies those who have achieved maximal SSTR saturation and would not derive additional benefit from further dose increases, preventing unnecessary drug exposure and cost. |
| Immunogenicity Assessment | During the clinical development of novel SSA formulations and biosimilars, immunogenicity assessment is mandated by regulatory agencies including the FDA and EMA. Octreotide ELISA kits validated according to regulatory guidelines are used to characterize ADA incidence, titers, neutralizing capacity, and their impact on pharmacokinetics. Post-marketing pharmacovigilance programs employ these kits for continued ADA surveillance, correlating immunogenicity with adverse events such as injection-site reactions and treatment-emergent resistance. |
| Translational Research | In the research laboratory, octreotide ELISA kits support investigations into SSTR biology, peptide - receptor interactions, and the pharmacodynamics of novel SSA conjugates. Preclinical models of NETs utilize these kits to measure tumor and plasma octreotide concentrations in xenograft studies, correlating drug exposure with antitumor efficacy and biomarker modulation. |
Octreotide remains an indispensable agent in the therapeutic armamentarium for neuroendocrine tumors, and the optimization of its clinical use through therapeutic drug monitoring is an increasingly recognized priority in precision oncology. Competitive ELISA kits provide a validated, accessible, and cost-effective platform for quantitative octreotide measurement in serum and plasma, supporting dose individualization, immunogenicity surveillance, and pharmacokinetic research. The combination of monoclonal antibody specificity, sub-nanogram sensitivity, and a streamlined 96-well workflow makes competitive ELISA the method of choice for routine octreotide TDM in both hospital-based clinical laboratories and contract research organizations. As the NET therapeutic landscape continues to evolve with new SSA formulations and combination regimens, reliable octreotide quantification will remain a cornerstone of evidence-based, patient-centered care.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-XYZ103 | Human Octreotide ELISA Kit | 96T | Human | Quantitative and Qualitative | sELISA | Inquiry |
| DEIA-JY25300 | Octreotide ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......
